AIM Fintech Glantus Holdings successfully rolling out buy & build strategy says CEO Maurice Healy. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,510.80
Bid: 1,502.00
Ask: 1,530.00
Change: 0.00 (0.00%)
Spread: 28.00 (1.86%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,510.80
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK, SK Bioscience to start Phase 3 Covid vaccine trial

(Sharecast News) - South Korea's SK Bioscience and the UK's GlaxoSmithKline on Tuesday said they would start a phase 3 clinical study of SK's Covid-19 vaccine candidate combined with GSK's pandemic vaccine booster

31 Aug 21 07:02

LONDON BROKER RATINGS: Berenberg ups price targets on Flutter, Entain

LONDON BROKER RATINGS: Berenberg ups price targets on Flutter, Entain

26 Aug 21 09:46

UPDATE 2-FTSE 100 inches higher as industrial miners jump

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* Rio Tinto jumps on restarting operations at Richards Bay* Engineering firm Wood drops on lower annual earnings forecast* Mid-caps hit reco...

24 Aug 21 09:13

UPDATE 2-AstraZeneca's antibody therapy prevents COVID-19, study shows

* Antibody combo 77% effective in preventing COVID-19* New hope for immunocompromised with low vaccine protection* AstraZeneca pursuing initial approval well before year-end (Adds further development, expected review, strategic implications)By Ludw...

20 Aug 21 07:53

UPDATE 3-AstraZeneca's antibody therapy prevents COVID-19, study shows

* Astra in frame to launch new prevention tool on top of vaccines* Antibody combo 77% effective in preventing COVID-19* New hope for immunocompromised with low vaccine protection* AstraZeneca pursuing initial approval well before year-end* (Adds ex...

20 Aug 21 07:53

Rentschler ready to start commercial production of CureVac COVID-19 shot

By Caroline CopleyBERLIN, Aug 19 (Reuters) - German contract drug manufacturer Rentschler Biopharma is in final preparations to start commercial production of CureVac's COVID-19 vaccine, its chief executive said, despite uncertainty over whether t...

19 Aug 21 14:30

Wednesday broker round-up

(Sharecast News) - Empiric Student: Berenberg downgrades to hold with 100.0p target price.

18 Aug 21 11:47

LONDON BROKER RATINGS: Berenberg ups Future price target after US deal

LONDON BROKER RATINGS: Berenberg ups Future price target after US deal

18 Aug 21 09:39

Tuesday broker round-up

(Sharecast News) - Future: ShoreCap stays at buy; Deutsche Bank keeps at buy and raises target price from 3,802.0p to 4,138.0p.

17 Aug 21 14:02

UPDATE 2-Energy, healthcare stocks lift FTSE 100; BHP Group shines

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window)* UK employment closer to pre-pandemic levels* BHP Group jumps on strong results* PLUS500 gains on robust revenue forecasts* FTSE 100 up 0.3%...

17 Aug 21 09:46

UPDATE 1-GSK, CureVac's next-gen COVID-19 vaccine shows promise in monkey trial

(Adds details on trial results, link to study)By Ludwig Burger and Yadarisa ShabongAug 16 (Reuters) - GlaxoSmithKline and CureVac said a study https://www.curevac.com/wp-content/uploads/2021/08/Optimization-of-Non-Coding-Regions-Improves-Protective-...

16 Aug 21 14:47

TOP NEWS: GSK, CureVac see promising pre-clinical data from Covid jab

TOP NEWS: GSK, CureVac see promising pre-clinical data from Covid jab

16 Aug 21 12:27

Sunday newspaper round-up: Meggitt, GlaxoSmithKline, Luxury goods

(Sharecast News) - Ministers must be prepared to block a takeover of Meggitt if any bidder tries to buy it without giving binding commitments on investment and jobs, the FTSE 250 aerospace and defence manufacturer's chairman warned this weekend. Sir Nigel Rudd said that while "clearly, price is important", any new owner would need to give Meggitt and the government undertakings, including to keep the company's headquarters in Coventry and maintain R&D spending. - Sunday Times

15 Aug 21 17:08

UK dividends calendar - next 7 days

UK dividends calendar - next 7 days

12 Aug 21 16:04

EXECUTIVE CHANGES: IDE CFO departs; Griffin hires former Dignity chair

EXECUTIVE CHANGES: IDE CFO departs; Griffin hires former Dignity chair

12 Aug 21 12:58

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.